ReviewJournal of endocrinological investigation2026
Thiazide therapy in chronic hypoparathyroidism: effects on hypercalciuria and renal function-a systematic review and exploratory meta-analysis.
Review in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management of Chronic Hypoparathyroidism and Hyperparathyroidism in Pregnancy/Lactation.Current osteoporosis reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeChronic hypoparathyroidism is associated with impaired renal calcium reabsorption, resulting in persistent hypercalciuria and increased risk of nephrolithiasis, nephrocalcinosis, and chronic kidney disease. Thiazide diuretics are commonly used to reduce urinary calcium excretion; however, evidence regarding their efficacy and renal safety remains limited. This study aimed to evaluate the effects of thiazide therapy on hypercalciuria and renal outcomes in patients with chronic hypoparathyroidism.
methodsA systematic search of PubMed/MEDLINE, Embase, Scopus, and Cochrane CENTRAL was conducted from inception to January 2026. Randomized and observational studies assessing thiazide therapy in adults with chronic hypoparathyroidism were included. Meta-analysis was performed using a random-effects model, with outcomes expressed as standardized mean differences (SMDs).
resultsFour studies involving 64 participants were included, comprising three physiological interventional studies and one randomized crossover trial. Two studies (n = 26) were eligible for quantitative synthesis. Meta-analysis showed no statistically significant reduction in urinary calcium excretion (SMD - 0.42; 95% CI - 4.64 to 3.80), with substantial imprecision. Qualitative evidence, including one randomized crossover trial, suggested reductions in urinary calcium excretion with thiazide therapy; however, pooled quantitative estimates remained inconclusive, and overall certainty of evidence was limited by small sample sizes, methodological heterogeneity, and short follow-up durations. Renal function remained stable across studies.
conclusionCurrent evidence suggests a possible reduction in urinary calcium excretion with thiazide therapy in chronic hypoparathyroidism; however, certainty remains low due to limited heterogeneous data and reliance on predominantly small physiological studies with only one randomized crossover trial. Quantitative pooled estimates were inconclusive, and definitive efficacy or long-term renal benefit remain unproven. Larger, well-designed prospective studies are needed to confirm efficacy and establish long-term renal safety. TRIAL REGISTRATION NUMBER: PROSPERO: CRD420261323680.
Indexed as
Identifiers
42287530What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.